Mary Jane Staab

1.2k total citations
24 papers, 982 citations indexed

About

Mary Jane Staab is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Immunology. According to data from OpenAlex, Mary Jane Staab has authored 24 papers receiving a total of 982 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Immunology. Recurrent topics in Mary Jane Staab's work include Prostate Cancer Treatment and Research (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immunotherapy and Immune Responses (8 papers). Mary Jane Staab is often cited by papers focused on Prostate Cancer Treatment and Research (18 papers), Cancer Immunotherapy and Biomarkers (10 papers) and Immunotherapy and Immune Responses (8 papers). Mary Jane Staab collaborates with scholars based in United States, Spain and Slovenia. Mary Jane Staab's co-authors include Glenn Liu, George Wilding, Douglas G. McNeel, Jens C. Eickhoff, Dorothea Horvath, Dona Alberti, Jane Straus, Laura E. Johnson, Joshua M. Lang and Rebecca Marnocha and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Mary Jane Staab

23 papers receiving 959 citations

Peers

Countries citing papers authored by Mary Jane Staab

Since Specialization

Citations

This map shows the geographic impact of Mary Jane Staab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Jane Staab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Jane Staab more than expected).

Fields of papers citing papers by Mary Jane Staab

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Jane Staab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Jane Staab. The network helps show where Mary Jane Staab may publish in the future.

Co-authorship network of co-authors of Mary Jane Staab

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Jane Staab. A scholar is included among the top collaborators of Mary Jane Staab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Jane Staab. Mary Jane Staab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Prime-boost vaccination targeting prostatic acid phosphatase (PAP) in patients with metastatic castration-resistant prostate cancer (mCRPC) using Sipuleucel-T and a DNA vaccine 2018 ·Journal for ImmunoTherapy of Cancer ·(unknown), Laura E. Johnson, Jens C. Eickhoff, (unknown), Mary Jane Staab, Glenn Liu, Douglas G. McNeel	48
2	Concurrent, but not sequential, PD-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer 2018 ·Oncotarget ·Douglas G. McNeel, Jens C. Eickhoff, (unknown), Christopher D. Zahm, Mary Jane Staab, Jane Straus, Glenn Liu	61
3	DNA vaccine with pembrolizumab to elicit antitumor responses in patients with metastatic, castration-resistant prostate cancer (mCRPC). 2017 ·Journal of Clinical Oncology ·Douglas G. McNeel, Jens C. Eickhoff, Robert Jeraj, Mary Jane Staab, Jane Straus, Brian T. Rekoske, Glenn Liu	10
4	MA 02.01 Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors 2017 ·Journal of Thoracic Oncology ·Ticiana Leal, Toby C. Campbell, Abigail C. Mapes, Kami Wolfe Schneider, Mary Jane Staab, Karen Velastegui, James G. Christensen, (unknown), Anne M. Traynor	4
5	Quantitative Total Bone Imaging in Patients with Metastatic Castration-Resistant Prostate Cancer Using NaF PET/CT. 2015 ·Journal of Clinical Oncology ·Glenn Liu, Scott B. Perlman, Timothy Perk, Stephanie A. Harmon, Mary Jane Staab, Robert Jeraj	1
6	Quantitative total bone imaging (QTBI) in patients with metastatic castration-resistant prostate cancer (CRPC) using NaF PET/CT. 2015 ·Journal of Clinical Oncology ·Glenn Liu, Scott B. Perlman, Timothy Perk, Stephanie A. Harmon, (unknown), Mary Jane Staab, Robert Jeraj	3
7	Real-Time Immune Monitoring to Guide Plasmid DNA Vaccination Schedule Targeting Prostatic Acid Phosphatase in Patients with Castration-Resistant Prostate Cancer 2014 ·Clinical Cancer Research ·Douglas G. McNeel, Jordan T. Becker, Jens C. Eickhoff, Laura E. Johnson, (unknown), (unknown), Mary Jane Staab, Glenn Liu, George Wilding, Brian M. Olson	48
8	Comparison of NaF and FDG PET/CT for Assessment of Treatment Response in Castration-Resistant Prostate Cancers With Osseous Metastases 2014 ·Clinical Genitourinary Cancer ·Urban Simončič, Scott B. Perlman, Glenn Liu, Mary Jane Staab, Jane Straus, Robert Jeraj	20
9	High resolution ultrasound features of prostatic rib metastasis: A prospective feasibility study with implication in the high-risk prostate cancer patient 2013 ·Urologic Oncology Seminars and Original Investigations ·Kenneth S. Lee, Arthur A. De Smet, Glenn Liu, Mary Jane Staab	4
10	A Randomized Phase II Trial Evaluating Different Schedules of Zoledronic Acid on Bone Mineral Density in Patients With Prostate Cancer Beginning Androgen Deprivation Therapy 2013 ·Clinical Genitourinary Cancer ·Joshua M. Lang, Marianne Wallace, Jordan T. Becker, Jens C. Eickhoff, Bjoern Buehring, Neil Binkley, Mary Jane Staab, George Wilding, Glenn Liu, Miroslav Malkovský, Douglas G. McNeel	11
11	Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma 2011 ·Cancer Immunology Immunotherapy ·Joshua M. Lang, (unknown), Marianne Wallace, Mary Jane Staab, Dorothea Horvath, George Wilding, Glenn Liu, Jens C. Eickhoff, Douglas G. McNeel, Miroslav Malkovský	114
12	Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancer 2011 ·Cancer Immunology Immunotherapy ·Douglas G. McNeel, Heath A. Smith, Jens C. Eickhoff, Joshua M. Lang, Mary Jane Staab, George Wilding, Glenn Liu	78
13	Phase I study of a DNA-based vaccine targeting prostatic acid phosphatase (PAP) in patients with clinical stage D0 prostate cancer 2007 ·Cancer Research ·Edward J. Dunphy, Mary Jane Staab, Dorothea Horvath, Jane Straus, Dona Alberti, Glenn Liu, George Wilding, Douglas G. McNeel	1
14	Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test 2007 ·Cancer Chemotherapy and Pharmacology ·Paul R. Hutson, Kurt R. Oettel, Jeff Douglas, (unknown), (unknown), Mary Jane Staab, Dona Alberti, (unknown), George Wilding	9
15	A Phase I Study of a DNA Vaccine Targeting Prostatic Acid Phosphatase in Patients with Stage D0 Prostate Cancer 2005 ·Clinical Genitourinary Cancer ·(unknown), Mary Jane Staab, (unknown), Jane Straus, (unknown), (unknown), (unknown), Dona Alberti, Glenn Liu, George Wilding, Jens C. Eickhoff, Douglas G. McNeel	12
16	Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma 2005 ·Investigational New Drugs ·(unknown), Kurt R. Oettel, Lynn Van Ummersen, Kyung Mann Kim, Yulin Zhang, Mary Jane Staab, (unknown), Rebecca Marnocha, Jeff Douglas, (unknown), Dona Alberti, George Wilding	9
17	A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer 2005 ·Clinical Cancer Research ·Christopher J. Sweeney, Glenn Liu, Constantin T. Yiannoutsos, Jill Kolesar, Dorothea Horvath, Mary Jane Staab, Karen Fife, Victoria Armstrong, Anthony M. Treston, Carolyn Sidor, George Wilding	146
18	Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer 2003 ·Investigational New Drugs ·Glenn Liu, Kurt R. Oettel, Howard H. Bailey, Lynn Van Ummersen, Kendra D. Tutsch, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Arzoomanian, (unknown), (unknown), Emily Robinson, David L. DeMets, George Wilding	45
19	Phase II study of 1alpha-hydroxyvitamin D(2) in the treatment of advanced androgen-independent prostate cancer. 2003 ·PubMed ·Glenn Liu, George Wilding, Mary Jane Staab, (unknown), (unknown), Amy Dresen, Dona Alberti, Rhoda Arzoomanian, Rick Chappell, Howard H. Bailey	63
20	Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer. 2002 ·PubMed ·Glenn Liu, Kurt R. Oettel, Gregory H. Ripple, Mary Jane Staab, Dorothea Horvath, Dona Alberti, Rhoda Arzoomanian, Rebecca Marnocha, Reginald C. Bruskewitz, Richard B. Mazess, Charles W. Bishop, Abhik Bhattacharya, Howard H. Bailey, George Wilding	57

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact